Esophagus Cancer Clinical Trial
Official title:
A Phase II, Prospective, Open-label Clinical Trial of Pre-Operative PD-1 Antibody (Toripalimab) + Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer
This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent Chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. And this study will provide valuable information for further clinical trials of preoperative Teripalimab and other immune checkpoint therapy in esophageal cancer treatment.
Esophageal cancer ranks the eighth most common cancer in Worldwide. And the third among men
and the fifth among women in China, among which esophageal squamous cell carcinoma accounts
for about 90%.
Neoadjuvant therapy for esophageal cancer is increasingly supported by evidence. However, the
results of neoadjuvant therapy are not completely consistent. Most studies of neoadjuvant
treatment data for esophageal cancer were obtained from western populations, where esophageal
adenocarcinoma and esophagogastric junction adenocarcinoma were more common and the sample
size was relatively small. According to the meta-analysis of the reported results of
randomized controlled trials, concurrent chemoradiotherapy has a higher pathological complete
response rate than chemotherapy alone as neoadjuvant therapy. However, the 3-year survival
rate of neoadjuvant chemoradiotherapy only showed an advantage in patients with squamous cell
carcinoma (56.8%vs42.8%), but no significant difference in patients with adenocarcinoma
(46.3%vs41.0%). Pathological complete remission rate of esophageal cancer after neoadjuvant
chemotherapy is relatively low.
It can be seen that positive expression of programmed death ligand-1 is more common in
Esophageal squamous cell carcinoma, and programmed death ligand-1 tends to be overexpressed
compared with adjacent normal epithelial cells. The later the T-stage of the tumor, the
higher the positive expression rate. In addition, programmed death ligand-1 expression is
significantly correlated with lymphatic metastasis. Therefore, programmed death ligand-1
expression can promote tumor progression. The recurrence rate of patients with programmed
death ligand-1 expression is higher after treatment, and the postoperative complete
pathological remission rate is lower in programmed death ligand-1 positive patients. In
addition, positive programmed death ligand-1 expression also reduces the sensitivity of
radiotherapy, which may be contributing factors to poor prognosis of patients with positive
pd-l1 expression. It is worth mentioning that clinical treatment will affect the expression
level of programmed death ligand-1 in esophageal cancer tissues. Neoadjuvant concurrent
chemoradiotherapy can up-regulate the expression of programmed death ligand-1 in ESCC
significantly, while neoadjuvant chemotherapy can down-regulate the expression of pd-L1.
However, radiotherapy can up-regulate the expression level of programmed death ligand-1 in
esophageal cancer cells, which is positively correlated with radiation dose, and the
combination of anti-pd-L1 therapy and radiotherapy can lead to increased tumor cell lysis,
which also indicates the importance of comprehensive treatment of tumor.
There are relatively few studies on the treatment of esophageal cancer with pd-1 / pd-L1
inhibitors. Keynote-059 enrolled 259 patients with advanced gastric or gastroesophageal
junction cancer in the phase II clinical trial of Pembrolizumab, with an objective response
rate of 11.6%, complete response rate of 2.3%, and median response duration of 8.4 months.
Persistent objective response rates were observed in both programmed death ligand-1 positive
and negative patients, and adverse reactions were tolerable.
The efficacy and safety of anti-pd-1 / pd-L1 therapy in the treatment of esophageal cancer
still need a lot of clinical studies to further confirm. This study will evaluate the safety
and feasibility of preoperative immune checkpoint therapy using pembrolizumab with concurrent
chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. And
this study will provide valuable information for further clinical trials of preoperative
Teripalimab and other immune checkpoint therapy in esophageal cancer.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT00201747 -
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
|
Phase 2 | |
Recruiting |
NCT06036563 -
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
|
||
Not yet recruiting |
NCT05023928 -
Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer
|
Phase 1 | |
Recruiting |
NCT03941626 -
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Recruiting |
NCT02988921 -
MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy
|
N/A | |
Completed |
NCT02979691 -
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
|
Phase 2/Phase 3 | |
Terminated |
NCT02797405 -
Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay
|
N/A | |
Recruiting |
NCT03347630 -
Pre-operative MRI of Esophagus Cancer
|
N/A | |
Completed |
NCT00193141 -
Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT05626309 -
Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer
|
N/A | |
Completed |
NCT05615129 -
Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
|
||
Recruiting |
NCT04821765 -
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
|
Phase 2 | |
Terminated |
NCT03108885 -
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
|
||
Recruiting |
NCT04046575 -
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
|
Phase 1 | |
Recruiting |
NCT06126406 -
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT03467529 -
Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study
|
||
Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 |